Drug
CMX001
CMX001 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Withdrawn1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
withdrawn125%
terminated125%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
NCT05391724
terminated
The Chimerix CMX001 Registry
NCT02167685
withdrawnphase_2
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
NCT02271347
completedphase_1
Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers
NCT00780182
Clinical Trials (4)
Showing 4 of 4 trials
NCT05391724Phase 1
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
NCT02167685
The Chimerix CMX001 Registry
NCT02271347Phase 2
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
NCT00780182Phase 1
Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4